Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $85.1 million.

  • Foghorn Therapeutics' Total Current Liabilities rose 49.74% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 49.74%. This contributed to the annual value of $67.0 million for FY2024, which is 14.64% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Total Current Liabilities stood at $85.1 million for Q3 2025, which was up 9.39% from $77.8 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Total Current Liabilities registered a high of $85.1 million during Q3 2025, and its lowest value of $16.3 million during Q1 2021.
  • Its 3-year average for Total Current Liabilities is $62.2 million, with a median of $56.8 million in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first spiked by 195.39% in 2022, then declined by 10.18% in 2024.
  • Foghorn Therapeutics' Total Current Liabilities (Quarterly) stood at $48.7 million in 2021, then climbed by 13.38% to $55.2 million in 2022, then rose by 5.85% to $58.4 million in 2023, then rose by 14.64% to $67.0 million in 2024, then spiked by 49.74% to $85.1 million in 2025.
  • Its Total Current Liabilities was $85.1 million in Q3 2025, compared to $77.8 million in Q2 2025 and $71.3 million in Q1 2025.